Brown F E, Nierenberg D W, Nordgren R E, Taylor R M, Rozycki A A
Department of Surgery, Dartmouth-Hitchcock Medical Center, Hanover, N.H.
Plast Reconstr Surg. 1991 May;87(5):961-4. doi: 10.1097/00006534-199105000-00026.
The occurrence of the rare but potentially fatal neuroleptic malignant syndrome must be considered by the surgeon treating a patient who develops hyperthermia, mental abnormalities, autonomic instability, and muscle rigidity after exposure to phenothiazines or other neuroleptic drugs. The dopamine agonist bromocriptine appears to be the treatment of choice in adults and seemed to be effective and well tolerated in our patient. Although the syndrome cannot be prevented, recognition is crucial, since effective general and specific therapy is available. Differentiating neuroleptic malignant syndrome from malignant hyperthermia allows early appropriate treatment with bromocriptine.
